Zinger Key Points
- "I would not touch this thing until it broke 500," Cramer on Lockheed Martin.
- It’s time to take profits in Omeros, says Cramer.
On CNBC's “Mad Money Lightning Round,” Jim Cramer said United Parcel Service, Inc. UPS has “screwed up a lot of holiday seasons.” He prefers FedEx Corporation FDX over UPS.
On Oct. 24, United Parcel Service reported better-than-expected third-quarter financial results.
It's time to take profits in Omeros Corporation (NASDAQ: OMER), Cramer said.
On Nov. 13, Omeros reported better-than-expected third-quarter earnings results.
When asked about Lockheed Martin Corporation LMT, he said, “I would not touch this thing until it broke 500. But it's run by Jim Taiclet [CEO of Lockheed Martin], and he's really fabulous.”
On Oct. 22, the company reported net sales growth of 1.3% year-over-year to $17.104 billion, missing the consensus of $17.351 billion. Adjusted EPS of $6.84, up from $6.77 in the prior year, topped the consensus of $6.50.
“I actually think these stocks have over-heated, and I am worried about a strong unemployment number on Friday,” Cramer said when asked about Archer Aviation Inc. ACHR.
On Nov. 7, Archer Aviation reported better-than-expected third-quarter earnings results.
The “Mad Money” host recommended taking a pass on AstraZeneca PLC AZN. “There's just been a series of disappointments. I don't know what to make of it,” he added.
On Nov. 12, AstraZeneca reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion. The company's adjusted EPADS reached $1.04, beating the consensus of $1.03. The adjusted EPS was $2.08 (1 ADR = 2 Common Shares).
Price Action:
- Lockheed Martin Corporation shares fell 1.1% to settle at $520.34 on Monday.
- UPS shares fell 1.3% to close at $134.02.
- Omeros shares gained 5.3% to close at $11.95 on Monday.
- Archer Aviation shares dipped 23.7% to close at $7.30.
- AstraZeneca shares fell 0.9% to settle at $67.04 on Monday.
Read Next:
Image: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.